Cresset Group Introduces New Support Resources for FieldStere

Published: Nov 30, 2011

Welwyn Garden City (30th Nov 2011) – Cresset has introduced a new range of support resources following the recent release of FieldStere V3.0, a key software tool aiding chemists in designing novel active molecules. In addition to phone, email and webinar support, Cresset now introduces software tutorial videos and case studies to provide insight into the features and benefits of FieldStere. The company anticipates that these resources will make the already intuitive software even more accessible to new users, and give experienced users a better understanding of FieldStere’s powerful real-world applications.

FieldStere is a software tool that enables molecule designers, including computational and medicinal chemists, to develop novel molecules with the same biological activity as an existing structure. The software provides suggestions for both core scaffold replacement and functional group changes. It has successfully been used by top Pharmaceutical, Biotech and Academic groups to find novel compounds and generate new intellectual property.

For further information on the complete range of software and services available from Cresset, please visit, follow Cresset on Twitter (@cressetgroup) or on LinkedIn.

About Cresset Group Ltd

Cresset develops software for calculating and comparing the molecular Field characteristics of chemical compounds. Field technology uses the surface properties of molecules to evaluate their activities and properties, rather than relying on 2D structure similarity, which enables Cresset’s users to find more interesting, novel and relevant results than other methods. Cresset’s Fields provide a smarter, structure independent way of hit-finding, lead switching and lead optimization in drug discovery and other chemistry-based research projects. Cresset’s Field technologies have been successfully applied to a very wide range of target classes, with and without structural information, on over 100 projects for major pharmaceutical and biotechnology companies.

Back to news